

An audit of efficacy and safety of Adalimumab therapy for non-infectious uveitis

Maroia Alsawaaiya

The Royal College of Surgeons, Ireland

Background: patients with untreated noninfectious uveitis (NIU) can get several complications as well as having side effects of corticosteroid which is the mainstay treatment for NIU. We did this audit to check the efficacy and safety of Adalimumab in patients with NIU.

Methods: This audit involved patients with intermediate, posterior and pan- noninfectious uveitis, in Royal Victoria Eye and Ear hospital in Dublin Ireland who received 80mg of Adalimumab as a loading dose and then 40mg every other week. All patients were given corticosteroid previously, which was then tapered down to 0mg. The mean outcomes we looked at are, BCVA, CMO, VH and the improvement of ocular symptoms.

Results: patients with bilateral uveitis had an improvement of 1.5 lines mean BCVA; whereas patients with unilateral uveitis had 2 lines loss. VH was improved in all patients whose data was collected. CMO improved by 9.95% in unilateral uveitis but dropped by 1.8% in the left eye in patients with bilateral uveitis. Side effects were reported in 48% of the cases.

Conclusion: In our study, Adalimumab was found to have a good efficacy in treating NIU, by improving vision and reducing the inflammation but it also caused some serious side effects.

Biography

Maroia Alsawaaiya MB, BCH, BAO (NUI, RCSI), LRCP & SI, graduated from the Royal College of Surgeons in Ireland 2020, currently doing her internship year in Sultan Qaboos University Hospital in Oman. She conducted her research in Royal Victoria Eye and Ear Hospital in Dublin. She publishes many articles in reputed journals.